Turn Therapeutics Inc. Appoints Martin Dewhurst to Board of Directors
Turn Therapeutics Inc. (Nasdaq: TTRX), a leading clinical-stage biotechnology company specializing in targeted therapies for inflammatory and immunological conditions, has announced the appointment of Mr. Martin Dewhurst to its Board of Directors as of January 7, 2026. This strategic move comes at a crucial moment for TTRX as the company intensifies its focus on mergers and acquisitions (M&A) to bolster its product pipeline and enhance long-term value.
About Martin Dewhurst’s Expertise
With over 30 years of global experience in the life sciences sector, Mr. Dewhurst brings significant expertise, particularly in mergers and acquisitions. He previously co-led the global life sciences practice at McKinsey & Company, where he gained extensive knowledge in biopharmaceuticals, medical technology, and genetics.
Bradley Burnam, Chief Executive Officer of Turn Therapeutics, commented, “Martin’s appointment comes at a pivotal moment for Turn Therapeutics as we advance a disciplined, M&A-focused strategy to expand our pipeline and accelerate long-term value creation. His insights will be instrumental as we evaluate accretive opportunities that complement our platform and position Turn for sustainable growth.”
Strategic Vision and Goals
Mr. Dewhurst expressed enthusiasm about joining Turn Therapeutics, stating, “I am honored to join the Board of Directors at Turn Therapeutics at an exciting point in the company’s evolution. Turn has built a differentiated platform addressing significant unmet needs across dermatology, wound care, and infectious disease.”
- Focus on disciplined portfolio expansion
- Value-enhancing partnerships
- Supporting long-term growth and organizational impact
Additional Roles and Accomplishments
In addition to his role at Turn Therapeutics, Mr. Dewhurst acts as a senior advisor to PJT Partners, a prominent M&A advisory bank, and as an external partner to Lightrock. He also holds board positions in various firms, including Distalmotion, a Switzerland-based medical technology company specializing in robotic surgery.
As a recognized expert, Mr. Dewhurst frequently shares his insights at prestigious forums, such as Bloomberg New Economy and the Milken Institute. His academic credentials include an undergraduate degree from Magdalen College, University of Oxford, and an MBA from INSEAD, where he graduated on the Dean's List.
About Turn Therapeutics Inc.
Turn Therapeutics Inc. focuses on developing and commercializing innovative solutions for dermatology, wound care, and infectious diseases. The company has achieved three FDA clearances for its proprietary formulations and is advancing its late-stage clinical programs in conditions like eczema and onychomycosis.
Moreover, Turn Therapeutics is actively engaged in global health initiatives, including efforts to improve vaccine delivery to underserved regions, illustrating its commitment to public health innovation.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including projections regarding the company's strategic plans and market opportunities. Although based on current expectations, these statements involve inherent risks and uncertainties. For more details on potential risks impacting TTRX's performance, refer to the company's filings with the SEC.
Contact Information
For further inquiries, please contact:
Sasha Damouni
Corporate Communications
Email: pr@turntherapeutics.com